MedPlus Health Services Releases Q4 FY26 Earnings Call Transcript
MedPlus Health Services released its Q4 FY26 earnings call transcript on May 26, 2026. The company plans to open 800 net new stores in FY27. Consolidated revenue was ₹18,644 million (1864.4 crore) with operating EBITDA at ₹1,076 million (107.6 crore). Pharmacy revenue grew 23.4% YoY. The company aims to maintain its private label sales growth trajectory.
The earnings call transcript provides detailed financial and operational updates, including store expansion plans and revenue figures. This information is crucial for investors and analysts to assess the company's performance and future outlook, thus having a medium impact on market perception.
The announcement is a transcript of an earnings call, which provides detailed operational and financial information. While the numbers presented are generally positive, the transcript itself is a factual reporting of a discussion and does not inherently contain strong positive or negative sentiment.
MedPlus Health Services Limited has submitted the transcript of its Earnings Call held on May 21, 2026, for the quarter and financial year ended March 31, 2026. The call, which included management commentary from CFO Mr. Sujit Mahato and Sr. Manager Finance Mr. DRN Srinivas, discussed key operational and financial highlights.
The company reported a net addition of 218 stores in Q4 FY26, with a plan to open 800 net new stores in FY27. The total store network grew to 5,330 stores, covering over 2.8 million square feet.
Consolidated revenue for Q4 FY26 stood at ₹18,644 million (1864.4 crore), with a consolidated operating EBITDA of ₹1,076 million (107.6 crore), representing a 5.8% margin. Revenue from pharmacy operations grew by 23.4% year-on-year. Stores older than 12 months contributed 96% of pharmacy revenue with a store-level EBITDA margin of 13.1%.
An update on working capital indicated net working capital at 53 days. A corrigendum noted that operating cash flows for FY26 were ₹4,956 million (495.6 crore), with an OCF by operating EBITDA ratio of 135.5%.
The diagnostics segment reported revenue of ₹1,309.9 million (130.99 crore) and operating EBITDA of ₹196 million (19.6 crore) for the year. For the quarter, diagnostics revenue grew to ₹347.8 million (34.78 crore) with an operating EBITDA of ₹53.1 million (5.31 crore).
Management addressed questions regarding store closures, emphasizing that a portion related to performance and relocation, while reassuring that the guidance for increasing private label sales remains intact. The company plans to continue expanding its network through both company-owned stores and franchisees, with a focus on refining the franchisee model for faster growth and profitability. MedPlus also highlighted its backward integration efforts in manufacturing certain non-pharma products and its continued focus on balanced growth across branded and private label offerings.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.